Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Next Previous
X
Search
Drug Profile

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Alternative Names: BMS-247616; CDHP/potassium-oxonate/tegafur; CIDU/potassium-oxonate/tegafur; Oteracil/tegafur/gimeracil; Potassium-oxonate/tegafur/CDHP; Potassium-oxonate/tegafur/CIDU; S-1; Tegafur/CDHP/potassium-oxonate; Tegafur/CIDU/potassium-oxonate; Tegafur/gimeracil/oteracil; Tegafur/potassium-oxonate/CDHP; Tegafur/potassium-oxonate/CIDU; Teysuno; TS-1; TS-1 combination capsules T20/T25; TS-1 combination granules T20/T25; TS-1 combination OD tablets T20/T25; TS-ONE

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Helsinki University Central Hospital; Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Carboxylic acids; Furans; Halogenated hydrocarbons; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Liver cancer; Oesophageal cancer; Squamous cell cancer; Uterine cancer
  • Phase II Gastrointestinal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 16 Mar 2023 Launched for HER2-negative-breast-cancer (Adjunctive treatment) in Japan (PO) prior to March 2023
  • 24 Nov 2022 Launched for HER2-negative-breast-cancer (Adjunctive treatment) in Japan (PO)
  • 24 Nov 2022 Launched for Pancreatic cancer (Inoperable/Unresectable) in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top